![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Blincyto Receives Expanded Approval From FDA
Blincyto Receives Expanded Approval From FDA
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
The FDA granted accelerated approval for Amgen’s Blincyto (blinatumomab) to treat children and adults with B-cell precursor acute lymphoblastic leukemia who are at risk of relapse.
The approval — FDA’s first for an MRD-positive ALL treatment — includes patients who have achieved remission from initial treatment for ALL but still have minimal residual disease.
Blincyto’s effectiveness was displayed in a single-arm clinical trial, and its side effects are consistent with those seen in other uses of the drug.
Upcoming Events
-
21Oct